Viewing Study NCT02025192

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:59 PM
Ignite Modification Date: 2026-05-22 @ 11:52 AM
Study NCT ID: NCT02025192
Status: COMPLETED
Last Update Posted: 2020-06-04
First Post: 2013-12-17
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer
Sponsor: Seagen Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None HER2 Positive Metastatic Breast Cancers View
Keywords:

Keywords

Keyword Brief Keyword Text View
None ONT-380 View
None Capecitabine View
None Trastuzumab View
None Xeloda View
None Herceptin View
None HER2 positive breast cancer View
None Breast cancer View
None ARRY-380 View
None Tucatinib View